预测卵巢癌复发的相关因素研究进展

赵晓婷; 马玲; 赵晓婷; 马玲

doi:10.13898/j.cnki.issn.1000-2200.2017.09.044

[1]

沈铿.复发性卵巢癌的诊断和治疗策略[J].现代妇产科进展,2005,14(3):177.

[2]

王新宇,叶菁,冯素文,等.血清CA125水平测定在预测卵巢上皮性癌复发和预后中的价值[J].中华妇产科杂志,2010,45(11):813.

[3]

高显忠,许树旭.现代肿瘤诊断治疗学[M].北京:科学技术文献出版社,2005:323.

[4]

李艳芳,李孟达.卵巢上皮性癌复发规律的探讨[J].癌症:英文版,2000,19(6):600.

[5]

刘穗,刘继红,黄鹤,等.上皮性卵巢癌复发的影响因素分析[J].癌症,2003,22(11):1197.

[6]

AYHAN A,CELIK H,TASKIRAN C,et al.Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer[J].Eur J Gynaecol Oncol,2002,24(3/4):223.

[7]

WINTER WE,MAXWELL GL,TIAN C,et al.Prognostic factors for stage Ⅲ epithelial ovarian cancer:a Gynecologic Oncology Group Study[J].J Clin Oncol,2007,25(24):3621.

[8]

彭素蓉,王金华,陈小祥.上皮性卵巢癌系统性腹膜后淋巴结切除术的临床意义[J].实用癌症杂志,2006,21(1):49.

[9]

BALBI G,MANGANARO MA,MONTEVERDE A,et al.Ovarian cancer:lymph node metastases[J].Eur J Gynaecol Oncol,2008,30(3):289.

[10]

CHAN JK,URBAN R,HU JM,et al.The potential therapeutic role of lymph node resection in epithelial ovarian cancer:a study of 13918 patients[J].British J Cancer,2007,96(12):1817.

[11]

MIKAMI M.Role of lymphadenectomy for ovarian cancer[J].J Gynecol Oncol,2014,25(4):279.

[12]

MAKHIJA S,HOWDEN N,EDWARDS R,et al.Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma:a retrospective review[J].Gynecol Oncol,2002,85(1):53.

[13]

NANNI C,RUBELLO D,FARSAD M,et al.¹⁸F-FDG PET/CT in the evaluation of recurrent ovarian cancer:a prospective study on forty-one patients[J].EJSO,2005,31(7):792.

[14]

顾欣,娄阁,张嘉文,等.¹⁸FDG-PET显像在监测卵巢癌复发和转移中的作用[J].实用肿瘤杂志,2007,21(3):270.

[15]

袁新荣,袁莉,张团英,等.糖链抗原125在预测卵巢癌复发中的价值[J].华南国防医学杂志,2012,5(1):17.

[16]

VAN DER BURG ME,LAMMES FB,VAN PUTTEN WL,et al.Ovarian cancer:the prognostic value of the serum half-life of CA125 during induction chemotherapy[J].Gynecol Oncol,1988,30(3):307.

[17]

黄立,姚嘉斐.血清CA125检测对卵巢上皮性癌预后的价值[J].中国妇幼保健,2005,20(13):1566.

[18]

LU R,SUN X,XIAO R,et al.Human epididymis protein 4(HE4) plays a key role in ovarian cancer cell adhesion and motility[J].Biochem Biophys Res Communicat,2012,419(2):274.

[19]

ZHU YF,GAO GL,TANG SB,et al.Effect of WFDC 2 silencing on the proliferation,motility and invasion of human serous ovarian cancer cells in vitro[J].Asian Pacif J Trop Med,2013,6(4):265.

[20]

MOLINA R,ESCUDERO JM,AUG? JM,et al.HE4 a novel tumour marker for ovarian cancer:comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases[J].Tum Biol,2011,32(6):1087.

[21]

YIGIT R,MASSUGER L,FIGDOR CG,et al.Ovarian cancer creates a suppressive microenvironment to escape immune elimination[J].Gynecol Oncol,2010,117(2):366.

[22]

THAVARAMARA T,PHALOPRAKARN C,TANGJITGAMOL S,et al.Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer[J].J Med Associat Thail,2011,94(7):871.

[23]

张文琪,郝权.术前外周血NLR对上皮性卵巢癌患者预后的影响[J].中国肿瘤临床,2014,41(10):634.

[24]

SO KA,HONG JH,JIN HM,et al.The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma:a retrospective cohort study[J].Gynecol Oncol,2014,132(3):551.

[25]

ZHANG H,GE T,CUI X,et al.Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling[J].Molecul Bio Syst,2015,11(2):516.

[26]

YUECHENG Y,XIAOYAN X.Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2[J].Eur J Cancer Prevent,2007,16(5):430.

[27]

YU Y,LI H,XUE B,et al.SDF-1/CXCR7 axis enhances ovarian cancer cell invasion by MMP-9 expression through p38 MAPK pathway[J].DNA Cell Biol,2014,33(8):543.

[28]

ACAR A,ONAN A,COSKUN U,et al.Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer[J].Med Oncol,2008,25(3):279.

[29]

SILLANPÄÄ SM,ANTTILA MA,VOUTILAINEN KA,et al.Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to β-catenin expression[J].Intern J Cancer,2006,119(8):1792.

[30]

LU J,GETZ G,MISKA E A,et al.MicroRNA expression profiles classify human cancers[J].Nature,2005,435(7043):834.

[31]

CAO J,CAI J,HUANG D,et al.miR-335 represents an independent prognostic marker in epithelial ovarian cancer[J].Am J Clin Pathol,2014,141(3):437.

[32]

LAIOS A,O'TOOLE S,FLAVIN R,et al.Potential role of miR-9 and miR-223 in recurrent ovarian cancer[J].Mol Cancer,2008,7(1):35.

[33]

HU X,MACDONALD DM,HUETTNER PC,et al.A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer[J].Gynecol Oncol,2009,114(3):457.

[34]

CHAO A,LIN CY,LEE YS,et al.Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2[J].Oncogene,2012,31(6):764.

[35]

FLAVIN R,SMYTH P,BARRETT C,et al.miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma[J].Intern J Gynecol Cancer,2009,19(4):641.